Inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp) are regarded as the most frequent and clinically important pharmacokinetic causes among the various possible factors for drug-drug interactions. Scutellarin is a flavonoid which is widely used for the treatment of cardiovascular diseases. In this study, the in vitro inhibitory effects of scutellarin on six major human CYPs (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and six rat CYPs (CYP1A2, CYP2C7, CYP2C11, CYP2C79, CYP2D4, and CYP3A2) activities were examined by using liquid chromatography-tandem mass spectrometry. Meanwhile, the inhibitory effects of scutellarin on P-gp activity were examined on a human metastatic malignant melanoma cell line WM-266-4 by calcein-AM fluorometry screening assay. Results demonstrated that scutellarin showed negligible inhibitory effects on the six major CYP isoenzymes in human/rat liver microsomes with almost all of the IC50 values exceeding 100 μM, whereas it showed values of 63.8 μM for CYP2C19 in human liver microsomes, and 63.1 and 85.6 μM for CYP2C7 and CYP2C79 in rat liver microsomes, respectively. Scutellarin also showed weak inhibitory effect on P-gp. In conclusion, this study demonstrates that scutellarin is unlikely to cause any clinically significant herb-drug interactions in humans when co-administered with substrates of the six CYPs (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and P-gp.
Introduction: Gut microbiota plays a key role in drug metabolism. While gut microbiota dysbiosis is known to contribute to hypertension pathogenesis, its impact on drug metabolism remains poorly considered. Clinically, the pharmacokinetic variability of losartan potassium is partially attributed to genetic polymorphisms of the CYP2C9 enzyme and structural variations in AGTR1. However, the potential role of gut microbiota dysbiosis in regulating losartan pharmacokinetics remains unclear. Methods: In the present study, we assessed the effect of gut microbiota dysbiosis on the metabolism and pharmacokinetics of losartan in two different rat models: spontaneously hypertensive rats (SHRs) with endogenous gut microbiota dysbiosis and rats with ceftriaxone (CRO)-induced gut microbiota dysbiosis combined with in vitro and in vivo studies. Results: The results showed that the intestinal flora from SHRs led to a more significant degradation of losartan than that from Wistar Kyoto rats (WKYs) in vitro . More importantly, we observed a reduction in the oral bioavailability of losartan in rats with gut microbiota dysbiosis. Specifically, compared to WKYs, the AUC 0-∞ of losartan and its active metabolite E-3174 decreased by 50.24% ( p < 0.05) and 72.42% ( p < 0.01), respectively, in SHRs. In the WKY + CRO group, losartan AUC 0-t decreased by 25.90% ( p < 0.05) compared to WKYs; while the SHR + CRO group showed a 57.20% ( p < 0.01) reduction compared to SHRs. Spearman correlation analysis of 16S rRNA full-length sequencing and pharmacokinetic parameters showed a significant negative correlation between Enterococcus faecalis ( E. faecalis ) abundance and losartan’s AUC 0-t and
C
max . In vitro experiments concluded that E. faecalis metabolized losartan and converted it into E-3179. The reduced oral bioavailability of losartan in rats with CRO-induced dysbiosis was likely due to the effect of E. faecalis in degrading losartan. Conclusion: This study highlights that gut microbiota dysbiosis diminishes losartan bioavailability, providing evidence that gut microbiota contributes to the pharmacokinetic variability of losartan.
Background: Ovarian cancer (OV) is the most prevalent and lethal gynecologic malignancy globally. Cisplatin remains the first-line chemotherapeutic regimen for OV; however, chemotherapy resistance poses a persistent clinical challenge in gynecologic oncology. Parthenolide, a naturally derived phytochemical, exhibits broad-spectrum antitumor activity. Recent studies suggest that parthenolide may reverse cisplatin-resistance in OV when used in combination therapy. This study aims to elucidate the molecular targets and mechanisms underlying parthenolide-mediated reversal of cisplatin-resistance by integrating network pharmacology and molecular docking approaches. Methods: Platinum-resistant and control OV gene expression datasets were retrieved from the gene expression omnibus database. Differentially expressed genes (DEGs) were identified using the limma R package. Cellular enrichment patterns in platinum-resistant and control samples were analyzed via single-sample Gene Set Enrichment Analysis (ssGSEA). Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify modules associated with differentially enriched cell types. A protein-protein interaction network of overlapping genes from DEGs and WGCNA-identified genes was constructed to pinpoint hub genes. Receiver operating characteristic (ROC) curves assessed the diagnostic utility of hub genes. Molecular docking and binding pocket analysis were performed to explore parthenolide-protein interactions. Results: A total of 3582 DEGs were identified between platinum-resistant and control samples, enriched in biological processes (e.g., cell junction assembly), cellular components (e.g., collagen-containing extracellular matrix), and molecular functions (e.g., signaling receptor activation). WGCNA revealed 331 genes correlated with differentially enriched cell types. Subsequent overlap analysis identified 266 immunity-related genes in platinum-resistant OV. Hub genes, including apolipoprotein E, demonstrated diagnostic value via ROC analysis. Molecular docking highlighted β2-microglobulin, brain-derived neurotrophic factor, cellular communication network factor 2, and activator protein-1 as parthenolide targets, with binding pocket analysis identifying critical interaction residues. Conclusions: This study identifies candidate genes linked to cisplatin-resistance and delineates molecular mechanisms by which parthenolide may counteract resistance, supporting its clinical application in OV therapy.